Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study.

Katherine E Kurgansky, Petra Schubert, Rachel Parker, Luc Djousse, Jerome B Riebman, David R Gagnon, Jacob Joseph
Author Information
  1. Katherine E Kurgansky: Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Veterans Affairs Boston Healthcare System, Boston, MA, USA.
  2. Petra Schubert: Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Veterans Affairs Boston Healthcare System, Boston, MA, USA.
  3. Rachel Parker: Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Veterans Affairs Boston Healthcare System, Boston, MA, USA.
  4. Luc Djousse: Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Veterans Affairs Boston Healthcare System, Boston, MA, USA.
  5. Jerome B Riebman: Amgen Inc., Thousand Oaks, CA, USA.
  6. David R Gagnon: Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Veterans Affairs Boston Healthcare System, Boston, MA, USA.
  7. Jacob Joseph: Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Veterans Affairs Boston Healthcare System, Boston, MA, USA. jjoseph16@partners.org. ORCID

Abstract

BACKGROUND: In a real-world setting, the effect of pulse rate measured at the time of diagnosis and serially during follow-up and management, on outcomes in heart failure with reduced ejection fraction (HFrEF), has not been well-studied. Furthermore, how beta-blockade use in a real-world situation modifies this relation between pulse rate and outcomes in HFrEF is not well-known. Hence, we identified a large, national, real-world cohort of HFrEF to examine the association of pulse rate and outcomes.
METHODS: Using Veterans Affairs (VA) national electronic health records we identified incident HFrEF cases between 2006 and 2012. We examined the associations of both baseline and serially measured pulse rates, with mortality and days hospitalized per year for heart failure and for any cause, using crude and multivariable Cox proportional hazards and Poisson or negative binomial models, respectively. The exposure was examined as continuous, dichotomous, and categorical. Post-hoc analyses addressed the interaction of pulse rate and beta-blocker target dose.
RESULTS: We identified 51,194 incident HFrEF cases (67 ± 12 years, 98% male, 77% white. A significant positive, near linear relationship was observed for both baseline and serially measured pulse rates with all-cause mortality, all-cause hospitalization and heart failure hospitalization after adjusting for covariates including beta-blocker use. Patients who had a pulse rate ≥ 70 bpm in the past 6 months had 36% (95% CI: 31-42%), 25% (95% CI: 19-32%), and 51% (95% CI: 33-72%) increased rates of mortality, all-cause hospitalization, and heart failure hospitalization, respectively, compared to patients with pulse rates < 70 bpm. A minority of subjects (15%) were treated with guideline directed beta blockade ≥50% of recommended target dose, among whom better outcomes were seen compared to those who did not achieve target dose in patients with pulse rates both above and below 70 beats per minute.
CONCLUSIONS: High pulse rate, both at the time of diagnosis and during follow-up, is strongly associated with increased risk of adverse outcomes in HFrEF patients, independent of the use of beta-blockers. In a real-world setting, the majority of HFrEF patients do not achieve target dose of beta-blockade; greater use of strategies to reduce heart rate may improve outcomes in HFrEF.

Keywords

References

  1. Am J Cardiol. 2010 Apr 1;105(7):905-11 [PMID: 20346304]
  2. Ann Intern Med. 2009 Jun 2;150(11):784-94 [PMID: 19487713]
  3. Am Heart J. 1987 Jun;113(6):1489-94 [PMID: 3591616]
  4. Clin Res Cardiol. 2013 Jan;102(1):11-22 [PMID: 22575988]
  5. J Am Coll Cardiol. 2017 Aug 8;70(6):776-803 [PMID: 28461007]
  6. J Am Coll Cardiol. 2017 Jun 20;69(24):2885-2896 [PMID: 28467883]
  7. Clin Exp Hypertens. 2004 Oct-Nov;26(7-8):637-44 [PMID: 15702618]
  8. J Am Coll Cardiol. 2018 Jul 24;72(4):351-366 [PMID: 30025570]
  9. Am J Cardiol. 2008 Mar 15;101(6):865-9 [PMID: 18328855]
  10. Eur Heart J. 2005 May;26(10):967-74 [PMID: 15774493]
  11. Drug Des Devel Ther. 2014 Jun 03;8:689-700 [PMID: 24940047]
  12. Lancet. 2010 Sep 11;376(9744):875-85 [PMID: 20801500]
  13. Lancet. 2010 Sep 11;376(9744):886-94 [PMID: 20801495]
  14. J Am Coll Cardiol. 2012 May 29;59(22):1938-45 [PMID: 22617188]
  15. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):3-11 [PMID: 29490032]
  16. JACC Heart Fail. 2013 Dec;1(6):488-96 [PMID: 24622000]
  17. Eur Heart J. 2006 Jan;27(1):65-75 [PMID: 16219658]
  18. J Am Coll Cardiol. 2012 May 15;59(20):1785-95 [PMID: 22575317]
  19. Cardiovasc Ther. 2010 Apr;28(2):93-100 [PMID: 20398098]
  20. Eur J Prev Cardiol. 2012 Feb;19(1):102-8 [PMID: 21525123]
  21. Eur J Heart Fail. 2012 Jul;14(7):737-47 [PMID: 22622001]
  22. Trends Cardiovasc Med. 2009 Jul;19(5):152-7 [PMID: 20005474]
  23. Circulation. 2014 Jun 10;129(23):2380-7 [PMID: 24799515]
  24. Lancet. 2008 Sep 6;372(9641):817-21 [PMID: 18757091]
  25. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30 [PMID: 17719466]
  26. JACC Heart Fail. 2016 Feb;4(2):109-115 [PMID: 26519996]
  27. Clin Res Cardiol. 2011 Jan;100(1):11-9 [PMID: 20809390]
  28. Am J Med. 2015 Oct;128(10):1102-1108.e6 [PMID: 26044936]
  29. Eur Heart J. 2008 May;29(10):1327-34 [PMID: 18375982]
  30. Diabetologia. 2012 May;55(5):1283-90 [PMID: 22286552]
  31. Circulation. 2017 Mar 7;135(10):e146-e603 [PMID: 28122885]

Grants

  1. SDR 02-237/HSRD VA
  2. Investigator Initiated Grant/Amgen

MeSH Term

Adrenergic beta-Antagonists
Aged
Aged, 80 and over
Electronic Health Records
Female
Heart Failure
Heart Rate
Hospitalization
Humans
Incidence
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Stroke Volume
Time Factors
United States
United States Department of Veterans Affairs
Ventricular Function, Left

Chemicals

Adrenergic beta-Antagonists

Word Cloud

Created with Highcharts 10.0.0pulserateHFrEFoutcomesheartfailureratesreal-worldusetargetdosehospitalizationpatientsmeasuredseriallyidentifiedmortalityall-cause95%CI:settingtimediagnosisfollow-upreducedejectionbeta-blockadenationalcohortincidentcasesexaminedbaselineperrespectivelybeta-blockerincreasedcomparedachieveHeartBACKGROUND:effectmanagementfractionwell-studiedFurthermoresituationmodifiesrelationwell-knownHencelargeexamineassociationMETHODS:UsingVeteransAffairsVAelectronichealthrecords20062012associationsdayshospitalizedyearcauseusingcrudemultivariableCoxproportionalhazardsPoissonnegativebinomialmodelsexposurecontinuousdichotomouscategoricalPost-hocanalysesaddressedinteractionRESULTS:5119467 ± 12 years98%male77%whitesignificantpositivenearlinearrelationshipobservedadjustingcovariatesincludingPatientsrate ≥ 70 bpmpast6 months36%31-42%25%19-32%51%33-72%< 70 bpmminoritysubjects15%treatedguidelinedirectedbetablockade≥50%recommendedamongbetterseen70beatsminuteCONCLUSIONS:Highstronglyassociatedriskadverseindependentbeta-blockersmajoritygreaterstrategiesreducemayimproveAssociationfraction:retrospectivestudyBeta-blockerHospitalizationMortalityOutcomes

Similar Articles

Cited By